Christopher Ryan Sullivan - Net Worth and Insider Trading

Christopher Ryan Sullivan Net Worth

The estimated net worth of Christopher Ryan Sullivan is at least $53 dollars as of 2024-05-10. Christopher Ryan Sullivan is the CFO of Avalo Therapeutics Inc and owns about 5 shares of Avalo Therapeutics Inc (AVTX) stock worth over $53. Details can be seen in Christopher Ryan Sullivan's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Christopher Ryan Sullivan has not made any transactions after 2023-06-09 and currently still holds the listed stock(s).

Transaction Summary of Christopher Ryan Sullivan

To

Christopher Ryan Sullivan Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Christopher Ryan Sullivan owns 1 companies in total, including Avalo Therapeutics Inc (AVTX) .

Click here to see the complete history of Christopher Ryan Sullivan’s form 4 insider trades.

Insider Ownership Summary of Christopher Ryan Sullivan

Ticker Comapny Transaction Date Type of Owner
AVTX Avalo Therapeutics Inc 2023-06-09 Interim CFO

Christopher Ryan Sullivan Latest Holdings Summary

Christopher Ryan Sullivan currently owns a total of 1 stock. Christopher Ryan Sullivan owns 5 shares of Avalo Therapeutics Inc (AVTX) as of June 9, 2023, with a value of $53.

Latest Holdings of Christopher Ryan Sullivan

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
AVTX Avalo Therapeutics Inc 2023-06-09 5 10.65 53

Holding Weightings of Christopher Ryan Sullivan


Christopher Ryan Sullivan Form 4 Trading Tracker

According to the SEC Form 4 filings, Christopher Ryan Sullivan has made a total of 4 transactions in Avalo Therapeutics Inc (AVTX) over the past 5 years, including 4 buys and 0 sells. The most-recent trade in Avalo Therapeutics Inc is the acquisition of 2 shares on June 9, 2023, which cost Christopher Ryan Sullivan around $1,748.

Insider Trading History of Christopher Ryan Sullivan

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Christopher Ryan Sullivan Trading Performance

GuruFocus tracks the stock performance after each of Christopher Ryan Sullivan's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Christopher Ryan Sullivan is -36.97%. GuruFocus also compares Christopher Ryan Sullivan's trading performance to market benchmark return within the same time period. The performance of stocks bought by Christopher Ryan Sullivan within 3 months outperforms 1 times out of 4 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Christopher Ryan Sullivan's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Christopher Ryan Sullivan

Average Return

Average return per transaction

Outperforming Transactions

1 out of 3 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -37.65
Relative Return to S&P 500(%) -39.03

Christopher Ryan Sullivan Ownership Network

Ownership Network List of Christopher Ryan Sullivan

No Data

Ownership Network Relation of Christopher Ryan Sullivan


Christopher Ryan Sullivan Owned Company Details

What does Avalo Therapeutics Inc do?

Who are the key executives at Avalo Therapeutics Inc?

Christopher Ryan Sullivan is the Interim CFO of Avalo Therapeutics Inc. Other key executives at Avalo Therapeutics Inc include director & 10 percent owner Armistice Capital Master Fund Ltd. , 10 percent owner Caissa Capital Management Ltd. , and Chief Medical Officer Garry Arthur Neil .

Avalo Therapeutics Inc (AVTX) Insider Trades Summary

Over the past 18 months, Christopher Ryan Sullivan made 1 insider transaction in Avalo Therapeutics Inc (AVTX) with a net purchase of 511. Other recent insider transactions involving Avalo Therapeutics Inc (AVTX) include a net purchase of 206,169 shares made by Caissa Capital Management Ltd. , a net sale of 3,233,542 shares made by Armistice Capital Master Fund Ltd. , and a net purchase of 6,083 shares made by Garry Arthur Neil .

In summary, during the past 3 months, insiders sold 0 shares of Avalo Therapeutics Inc (AVTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 15,348 shares of Avalo Therapeutics Inc (AVTX) were sold and 2,762 shares were bought by its insiders, resulting in a net sale of 12,587 shares.

Avalo Therapeutics Inc (AVTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Avalo Therapeutics Inc Insider Transactions

No Available Data

Christopher Ryan Sullivan Mailing Address

Above is the net worth, insider trading, and ownership report for Christopher Ryan Sullivan. You might contact Christopher Ryan Sullivan via mailing address: C/o Cerecor Inc., 400 E. Pratt Street, Suite 606, Baltimore Md 21202.

Discussions on Christopher Ryan Sullivan

No discussions yet.